<DOC>
	<DOCNO>NCT01672762</DOCNO>
	<brief_summary>This study evaluate safety efficacy ASP1941 24 week administration diabetic patient .</brief_summary>
	<brief_title>A Study Evaluate Long-term Safety Efficacy ASP1941 Diabetes Patients</brief_title>
	<detailed_description>Subjects undergo 6-week screening period enter 24-week treatment period receive ASP1941 breakfast treatment period . All subject follow 4 week study treatment discontinue .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>Type 2 diabetes mellitus patient Subject diet exercise program receive single antihyperglycemic agent two antihyperglycemic agent ( exclude insulin ) low dose ( ≤50 % maximum dose recommend dosage ) Subject HbA1c value ( JDS value ) 6.5 % 9.5 % difference HbA1c value ( JDS value ) within ± 1.0 % BMI 20.0 45.0 kg/m2 Type 1 Diabetes Mellitus Subject receive insulin within 12 week ( 84 day ) study Subject proliferative diabetic retinopathy Subject history clinically significant renal disease renovascular occlusive disease , nephrectomy and/or renal transplant Subject obvious dysuria cause neurogenic bladder benign prostatic hypertrophy Subject history cerebral vascular attack , unstable angina , myocardial infarction , vascular intervention , heart disease ( NYHA Class IIIIV ) within 12 week ( 84 day ) . Subject heart disease , cerebral vascular disease , opinion principal investigator subinvestigator , may interfere treatment evaluation safety study . Female subject currently pregnant lactating , possibly pregnant Male premenopausal Female subject use appropriate contraception study Subject history treatment ASP1941 Subject participate another clinical study , post marketing study , medical equipment study within 12 week ( 84 day ) provide write informed consent , currently participate study Subject serum creatinine value high upper limit normal range Subject urinary microalbumin/ urinary creatinine ratio &gt; 300 mg/g urinalysis Subject uncontrolled severe hypertension ( subject whose systolic blood pressure &gt; 170 mmHg diastolic blood pressure &gt; 95 mmHg measure sit position 5 minute rest Subject judge inappropriate enrollment study principal investigator subinvestigator</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>diabetes mellitus</keyword>
	<keyword>serum Insulin</keyword>
	<keyword>blood glucose</keyword>
	<keyword>glucose excretion</keyword>
	<keyword>hypoglycemic agent</keyword>
	<keyword>ipragliflozin</keyword>
</DOC>